Studying Alzheimer's disease through an integrative serum metabolomic and lipoproteomic approach.

ABSTRACT:

Background

Alzheimer's disease (AD) is the most frequent neurodegenerative disorder worldwide. The great variability in disease evolution and the incomplete understanding of the molecular mechanisms underlying AD make it difficult to predict when a patient will convert from prodromal stage to dementia. We hypothesize that metabolic alterations present at the level of the brain could be reflected at a systemic level in blood serum of patients, and that these alterations could be used as prognostic biomarkers.

Methods

This pilot study proposes a serum investigation via nuclear magnetic resonance (NMR) spectroscopy in a consecutive series of AD patients including 57 patients affected by Alzheimer's disease at dementia stage (AD-dem) and 45 patients with mild cognitive impairmen

SUBMITTER: Vignoli A 

PROVIDER: S-EPMC11773822 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature